Scarica l'app Stockscreener
4.22
4.95%
-0.22
Pre-mercato:
2.50
-1.72
-40.76%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ADIL Giù?
Forum
Previsione
Frazionamento azionario
Adial Pharmaceuticals Inc Borsa (ADIL) Ultime notizie
Adial Pharmaceuticals to replace CEO and CFO after 2026 annual meeting - scanx.trade
Director at Adial Pharma (NASDAQ: ADIL) gets 25,666 stock options - Stock Titan
Adial Shareholders Approve Key Proposals, Meeting Adjourned - TipRanks
Adial Pharmaceuticals Amends Agreements to Restore Nasdaq Compliance - TipRanks
Adial Pharmaceuticals Removes Penalty Provisions in PIPE and Note Exchange to Restore Nasdaq Compliance - TradingView
Why Did Adial Pharmaceuticals (ADIL) Stand Out? - Kalkine Media
ADIL Should I Buy - Intellectia AI
Adial Pharmaceuticals Inc Warrant (ADILW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Adial Pharmaceuticals files prospectus for resale of 25.1 million shares - scanx.trade
Lucid Capital initiates coverage on Adial with Buy rating - scanx.trade
Adial PharmaceuticalsProposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling StockholdersSEC Filing - TradingView
Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Adial (ADIL) Financial Update: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Session Move - vinanet.vn
Adial (ADIL) Shares: Finishes 14.56% Down at $5.31; Current Setup: the Current Price Sits Inside the Supplied Technical Range at the CloseSign of Strength - dars.gov.et
Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge - TipRanks
Adial Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Adial (ADIL) Watch: Ends Up by 5.42% at $6.22 in the Latest Reading; Price Context: $5.91 and $6.53 Define the Nearby Reference Levels in the Latest SessionSkew Index - vinanet.vn
Adial (ADIL) Financial Update: EPS Exceeds Its Estimate on the Day; Post-Report Move: Shares Move 9.22% Up at the CloseRevenue Breakdown Analysis - vinanet.vn
Adial Pharmaceuticals (ADIL) Jumps 15% as Trading Volume AcceleratesFade Trade - vinanet.vn
Adial Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Adial Closes $32M Tranche of $64M Financing for Ulcerative Colitis Drug Development - Minichart
Form 8K Adial Pharmaceuticals Inc For: 17 August By Investing.com - Investing.com Nigeria
Weekly Recap: Cash shortfall, warrant reliance and CEO succession, CFO exit - TradingView
Adial Reports $52 Million Second-Quarter Net Loss After Azora Acquisition - Quiver Quantitative
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update - The Manila Times
ADIL Q1 2026 Earnings: EPS Surprise Amid Revenue AbsenceDividend Growth Analysis - vinanet.vn
Adial Pharmaceuticals (ADIL) Slides 9.3% as Biotech Volatility ReturnsSector Leader Stocks - dars.gov.et
Adial Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Adial Pharmaceuticals (NASDAQ: ADIL) lifts cash to $28.7M but flags going‑concern risk - Stock Titan
Form 8K Adial Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Canada
Adial Pharmaceuticals plans leadership changes tied to annual meeting vote - Investing.com
Adial Pharmaceuticals Plans Major Leadership and Board Transition - TipRanks
ADIL Q1 2026 Earnings: Narrower-than-Expected Loss Delivers 46.85% Positive SurpriseCash Flow Report - Vinanet
Adial Pharmaceuticals Acquires Azora Therapeutics in Stock-and-Preferred Deal - Minichart
Adial Pharmaceuticals announces annual shareholder meeting - Bitget
Form 8K Adial Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Canada
Adial Pharmaceuticals (NASDAQ: ADIL) outlines Azora merger, heavy dilution and $53M share overhang - Stock Titan
Adial Pharmaceuticals Inc expected to post a loss of $1.03 a shareEarnings Preview - TradingView
Adial Pharmaceuticals (ADIL) Plunges 17% as Shares Test Key $3.78 Support LevelSafe Entry Stocks - careplusvn.com
Adial Pharmaceuticals Price Target Announced at $11.00/Share by Alliance Global Partners - Moomoo
Adial Pharmaceuticals Initiated at Buy by Alliance Global Partners - Moomoo
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
A. G. P. Initiates Adial Pharmaceuticals(ADIL.US) With Buy Rating, Announces Target Price $11 - moomoo.com
ADIL Q1 2026 Earnings: EPS Beats Estimates Sharply, But Revenue Remains AbsentEarnings Revision Downgrade - careplusvn.com
ADIL Q1 2026 Earnings: Narrower-than-Expected Loss Fuels 4.44% Share UptickFinancial Data - Vinanet
Adial Pharmaceuticals Inc (ADIL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Adial Pharmaceuticals Inc (ADIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Adial Pharmaceuticals Inc (ADIL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Adial Pharmaceuticals Inc (ADIL) Institutional Confidence - TradingKey
Adial Pharmaceuticals Inc (ADIL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ADIL|Adial Pharmaceuticals Inc|Price:2.860|Chg%:+0.080 - TradingKey
Adial Pharmaceuticals Inc (ADIL) Cash Flow - tradingkey.com
ADIL|Adial Pharmaceuticals Inc|Price:4.400|Chg%:+0.090 - TradingKey
Adial Pharmaceuticals, Inc Revenue Breakdown – NASDAQ:ADIL - TradingView
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):